Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Equity Average (2023 - 2025)

Silence Therapeutics' Equity Average history spans 3 years, with the latest figure at $68.2 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 47.7% to $68.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $68.2 million, a 47.7% decrease, with the full-year FY2025 number at $98.2 million, up 25.84% from a year prior.
  • Equity Average hit $68.2 million in Q4 2025 for Silence Therapeutics, down from $84.1 million in the prior quarter.
  • Over the last five years, Equity Average for SLN hit a ceiling of $149.6 million in Q2 2024 and a floor of $20.3 million in Q3 2023.
  • Historically, Equity Average has averaged $92.6 million across 3 years, with a median of $96.2 million in 2025.
  • Biggest five-year swings in Equity Average: soared 562.0% in 2024 and later crashed 47.7% in 2025.
  • Tracing SLN's Equity Average over 3 years: stood at $23.2 million in 2023, then surged by 460.77% to $130.4 million in 2024, then tumbled by 47.7% to $68.2 million in 2025.
  • Business Quant data shows Equity Average for SLN at $68.2 million in Q4 2025, $84.1 million in Q3 2025, and $103.4 million in Q2 2025.